Interlaboratory and interstudy reproducibility of a novel lateral- Flow device and influence of antifungal therapy on detection of invasive pulmonary aspergillosis

Journal of Clinical Microbiology

Volumn 51, Issue 2, 2013, Pages 459-465

  Wiederhold, Nathan P ^a,b   Najvar, Laura K ^a,c   Bocanegra, Rosie ^a,c   Kirkpatrick, William R ^a,c   Patterson, Thomas F ^a,c   Thornton, Christopher R ^d  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^d UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; BETA 1,3 GLUCAN; CASPOFUNGIN; GALACTOMANNAN; IMMUNOGLOBULIN G ANTIBODY; POSACONAZOLE; VORICONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPERGILLUS FUMIGATUS; ASSAY; BLOOD; CONTROLLED STUDY; GUINEA PIG; HISTOPATHOLOGY; LATERAL FLOW DEVICE; LUNG ASPERGILLOSIS; LUNG LAVAGE; MALE; NEUTROPENIA; NONHUMAN; PATHOGEN LOAD; POINT OF CARE TESTING; PRIORITY JOURNAL; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLUS; BRONCHOALVEOLAR LAVAGE FLUID; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; GLUCANS; GUINEA PIGS; HUMANS; INVASIVE PULMONARY ASPERGILLOSIS; MALE; MANNANS; POINT-OF-CARE SYSTEMS; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 84873023897     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02142-12     Document Type: Article

References (26)

1. Lin SJ, Schranz J, Teutsch SM. 2001. Aspergillosis case-fatality rate: systematic review of the literature. Clin. Infect. Dis. 32:358 -366.
2. Caillot D, Casasnovas O, Bernard A, Couaillier JF, Durand C, Cuisenier B, Solary E, Piard F, Petrella T, Bonnin A, Couillault G, Dumas M, Guy H. 1997. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J. Clin. Oncol. 15:139 -147.
3. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, Bearden DT. 2006. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin. Infect. Dis. 43:25-31.
4. Greene RE, Schlamm HT, Oestmann JW, Stark P, Durand C, Lortholary O, Wingard JR, Herbrecht R, Ribaud P, Patterson TF, Troke PF, Denning DW, Bennett JE, de Pauw BE, Rubin RH. 2007. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin. Infect. Dis. 44:373-379.
5. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360.
6. Marr KA, Laverdiere M, Gugel A, Leisenring W. 2005. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin. Infect. Dis. 40:1762-1769.
7. McCulloch E, Ramage G, Rajendran R, Lappin DF, Jones B, Warn P, Shrief R, Kirkpatrick WR, Patterson TF, Williams C. 2012. Antifungal treatment affects the laboratory diagnosis of invasive aspergillosis. J. Clin. Pathol. 65:83- 86.
8. Senn L, Robinson JO, Schmidt S, Knaup M, Asahi N, Satomura S, Matsuura S, Duvoisin B, Bille J, Calandra T, Marchetti O. 2008. 1, 3-beta-DGlucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin. Infect. Dis. 46:878-885.
9. Iweala OI. 2004. HIV diagnostic tests: an overview. Contraception 70: 141-147.
10. Jarvis JN, Percival A, Bauman S, Pelfrey J, Meintjes G, Williams GN, Longley N, Harrison TS, Kozel TR. 2011. Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin. Infect. Dis. 53:1019-1023.
11. Ketema F, Zeh C, Edelman DC, Saville R, Constantine NT. 2001. Assessment of the performance of a rapid, lateral flow assay for the detection of antibodies to HIV. J. Acquir. Immune Defic. Syndr. 27:63-70.
12. Sharma SK, Eblen BS, Bull RL, Burr DH, Whiting RC. 2005. Evaluation of lateral-flow Clostridium botulinum neurotoxin detection kits for food analysis. Appl. Environ. Microbiol. 71:3935-3941.
13. Smits HL, Eapen CK, Sugathan S, Kuriakose M, Gasem MH, Yersin C, Sasaki D, Pujianto B, Vestering M, Abdoel TH, Gussenhoven GC. 2001. Lateral-flow assay for rapid serodiagnosis of human leptospirosis. Clin. Diagn. Lab. Immunol. 8:166 -169.
14. Thornton CR. 2008. Development of an immunochromatographic lateral- flow device for rapid serodiagnosis of invasive aspergillosis. Clin. Vaccine Immunol. 15:1095-1105.
15. Wiederhold NP, Thornton CR, Najvar LK, Kirkpatrick WR, Bocanegra R, Patterson TF. 2009. Comparison of lateral flow technology and galactomannan and (1¡3)-beta-D-glucan assays for detection of invasive pulmonary aspergillosis. Clin. Vaccine Immunol. 16:1844 -1846.
16. Hoenigl M, Koidl C, Duettmann W, Seeber K, Wagner J, Buzina W, Wolfler A, Raggam RB, Thornton CR, Krause R. 2012. Bronchoalveolar lavage lateral-flow device test for invasive pulmonary aspergillosis diagnosis in haematological malignancy and solid organ transplant patients. J. Infect. 65:588 -591.
17. Thornton C, Johnson G, Agrawal S. 2012. Detection of invasive pulmonary aspergillosis in haematological malignancy patients by using lateralflow technology. J. Vis. Exp. Pii=e3721. doi:10.3791/3721.
18. Vallor AC, Kirkpatrick WR, Najvar LK, Bocanegra R, Kinney MC, Fothergill AW, Herrera ML, Wickes BL, Graybill JR, Patterson TF. 2008. Assessment of Aspergillus fumigatus burden in pulmonary tissue of guinea pigs by quantitative PCR, galactomannan enzyme immunoassay, and quantitative culture. Antimicrob. Agents Chemother. 52:2593-2598.
19. Sheppard DC, Rieg G, Chiang LY, Filler SG, Edwards JE Jr, Ibrahim AS. 2004. Novel inhalational murine model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 48:1908 -1911.
20. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academies Press, Washington, DC.
21. Sheppard DC, Graybill JR, Najvar LK, Chiang LY, Doedt T, Kirkpatrick WR, Bocanegra R, Vallor AC, Patterson TF, Filler SG. 2006. Standardization of an experimental murine model of invasive pulmonaryy aspergillosis. Antimicrob. Agents Chemother. 50:3501-3503.
22. Associates of Cape Cod Inc. 2008. Assay for (1, 3)-beta-D-glucan in serum. Associates of Cape Cod Inc, East Falmouth, MA.
23. Morelle W, Bernard M, Debeaupuis JP, Buitrago M, Tabouret M, Latge JP. 2005. Galactomannoproteins of Aspergillus fumigatus. Eukaryot. Cell 4:1308 -1316.
24. Stynen D, Goris A, Sarfati J, Latge JP. 1995. A new sensitive sandwich enzyme-linked immunosorbent assay to detect galactofuran in patients with invasive aspergillosis. J. Clin. Microbiol. 33:497-500.
25. Stynen D, Sarfati J, Goris A, Prevost MC, Lesourd M, Kamphuis H, Darras V, Latge JP. 1992. Rat monoclonal antibodies against Aspergillus galactomannan. Infect. Immun. 60:2237-2245.
26. Wiederhold NP, Thornton CR. 2011. Lack of cross-reactivity and interference of commonly used intravenous antimicrobials with a lateral-flow device for the diagnosis of invasive aspergillosis, abstr M-1538. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL. American Society for Microbiology, Washington, DC.